Wire · regulatory
Dr. Reddy's Laboratories Receives US FDA Approval For Rituximab Biosimilar
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 August 2026 · Fusion42 review
Dr. Reddy's Laboratories has received U.S. FDA approval for its rituximab biosimilar, enabling commercialisation in the United States through partner Fresenius Kabi. This regulatory milestone positions the company for a significant medium-to-long term revenue opportunity in the competitive U.S. biosimilars market.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 1 Aug 2026 and 14 Aug 2026.
◆ ◆ The Wire takeaway
Your biotech firm must adjust to tougher US biologics competition now that Dr. Reddy's has entered with an FDA-approved biosimilar. Watch Fresenius Kabi's US launch closely as it shapes market access and pricing you will face this year.
◆ Coverage
5 sources · first reported 1 Aug 2026 · latest 14 Aug 2026
◆ Related on Wire
◆ Topics